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Background: A postacute phase needs reliable routine screening instruments in order to identify 
the patients to be referred for a clinical interview with a psychologist. The aim of this study 
was to estimate the clinical cutoff scores of the anxiety and depression questionnaires and their 
clinical validity using a gold standard.
Methods: The study involved 177 patients with pulmonary, cardiac, or neurological disease 
undergoing in-hospital rehabilitation. Receiver operating characteristic curves were used to 
determine the best concordance between questionnaire’s scores and the gold standards.
Results: There was a significant difference (P,0.001) between clinically anxious and depressed 
patients and nonclinical subjects. The receiver operating characteristic curve for anxiety indicated 
that the best area under the curve for State Anxiety Inventory is obtained with a cutoff point of 21 for 
males and 25 for females; for depression scores, the highest area under the curve for Depression 
Questionnaire-Reduced Form is obtained with a cutoff point of six for males and eight for females.
Conclusion: Using appropriate cutoff values, the State Anxiety Inventory and Depression 
Questionnaire-Reduced Form allow psychologists to optimize early clinical intervention strate-
gies selecting patients with significant needs.
Keywords: anxiety, depression, questionnaire, sensitivity and specificity, rehabilitation
Introduction
Many studies have established the presence of a high rate of psychological complaints 
among nonpsychiatric hospital patients.1 Symptoms of anxiety and depression 
may confuse a patient’s clinical image, reduce compliance with therapeutic pro-
grams and affect the medium- or long-term outcomes pursued during the course of 
hospitalization,2–4 predict health-related quality of life,5 and predict the influence of 
symptoms of anxiety and depression on medication noncompliance.6,7
The American Heart Association recently published a Science Advisory with the 
recommendation that patients with coronary heart disease (CHD) should be screened 
for depressive symptoms.8–10 Ziegelstein et al11 maintain that for routine screening of 
CHD patients for depression to be recommended, screening tests must be sufficiently 
sensitive, specific, and validated, because cutoff scores used in primary care may not 
work equivalently in patients with CHD.12 In a very recent review,13 it is noted that 
there are few examples of screening tools with high sensitivity and specificity using 
an a priori defined cutoff score in .1 CHD sample.
Mild-to-moderate symptoms of anxiety and/or depression have also been 
observed in patients with chronic obstructive pulmonary disease (COPD) and current 
recommendations indicate that they should not be ignored. Appropriate outcome measures 
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for mental health are needed for this patient population.14 Simi-
larly, depression and anxiety were significant for the outcomes 
regarding readmissions to hospital or death 6 months after a 
stroke. These are the reasons why clinicians need to identify 
specific patients with stroke with preexisting mental health 
conditions for which additional psychotherapy treatment may 
result in improved stroke outcomes.15
A Cochrane review16 indicated that psychological interven-
tion in CHD patients did produce small to moderate improve-
ments in depression and anxiety but there was no consistent 
evidence of a positive effect on health-related quality-of-life 
(HRQOL) or other psychological outcomes, including per-
ceived stress, Type-A behavior, anger, and perceived exhaus-
tion or Vital Exhaustion. All the aforementioned reasons and 
results support our search for clinical level of anxiety or depres-
sion in a rehabilitation setting and that both will be specific to 
the medical conditions of the patients concerned.
The aim of this study was to use receiver operating 
characteristic (ROC) curves to determine the best concor-
dance between STAI-X3 and Depression Questionnaire-
Reduced Form (acronym AD-R) scores using the opinion 
of a psychologist after a semi-structured clinical interview 
as gold standard.
Materials and methods
Patient population and data collection
The present observational study involved consecutively 
enrolled patients with pulmonary, cardiac, or neurological and 
neuromuscular disease undergoing in-hospital rehabilitation at 
the Salvatore Maugeri Foundation, IRCCS, Scientific Institute 
Division of Respiratory, Cardiac, and Neuromotor Rehabilita-
tion during a period of 6 months in 2010. As a rule, the subjects 
completed the AD-R within the second to third day from the 
hospital admission. On the same day, a psychologist inde-
pendently assessed their anxiety and depression status using 
a semistructured interview17,18 and decided the appropriate 
psychological support needed. The psychologist was blinded 
to the AD-R scores. Exclusion criteria were as follows: the 
inability to complete questionnaires and a history of a severe 
psychiatric disease. The protocol was reviewed and approved 
by an internal review board for ethical protection of subjects 
(Comitato Tecnico Scientifico), and written informed consent 
of all the participants was obtained.
Measures
With the aim of making the screening process more rapid 
and accurate, we developed the ten-item version of the State 
Anxiety Inventory (STAI-X3)19–21 and the 15-item QD-R both 
with validated and reliable criteria (concurrent and predictive 
content).22,23 The reduced form of STAI-X3, consists of 
10 items asking the subjects how they feel “right now” that 
are scored using a 4-point Likert scale (total score 10–40). 
The QD-R measures depressive symptoms and was originally 
constructed with reference to Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-III and meets all of the 
DSM-IV Revised24 criteria for major depressive disorder 
(depressed mood; loss of interest or pleasure; variations in 
appetite and weight; insomnia/hypersomnia; psychomotor 
agitation/slowing; fatigability; self-depreciation; poor con-
centration; recurrent thoughts of death). For more details on 
the reduction methods, see Vidotto et al.22 The two question-
naires in the reduced form take ~5 minutes to complete.
It simplifies screening of patients in hospital settings as 
it is suitable for subjects with mild/moderate or subclinical 
depression.22,23 The QD-R has 15 items, each consisting 
of a statement (eg, “The future looks very bleak”) to be 
answered “yes” or “no” (total score 0–15) and excludes 
somatic symptoms, thereby avoiding potential confound-
ing by the somatic symptoms in hospitalized patients. The 
instructions ask that the questions should be answered 
“thinking about how you feel at this moment”, with the 
subject being asked to ponder the time span corresponding 
to that required to complete the survey.
Using Cronbach’s alpha score, the internal consistency of 
the QD-R is 0.77; any value between 0.7 and 0.8 is consid-
ered satisfactory for comparing groups.25 STAI-X3 showed 
an internal consistency assessed with Cronbach’s alpha of 
0.90 in healthy subjects.20
semistructured clinical interview: gold 
standard
In order to structure and maintain a single criterion for 
defining the gold standard, we used a “semistructured clini-
cal interview” form based on and in respect of the DSM-IV 
anxiety and depression (DSM code 300.4) criteria. Inter-rater 
agreement with the psychological judgment for anxiety state 
(Cohen’s K =3.60; concordance 76%) and for depressive 
reaction (Cohen’s K =2.39; concordance =86%) has been 
found in a previously published study.17 The “semistructured 
clinical interview” form is divided into three sections: anxi-
ety, depression, and an area in which the diagnostic criteria 
for such disturbances overlap.
The interview began with a series of unstructured ques-
tions with the aim of establishing a cooperative relationship 
between the patient and the psychologist, and acquiring diag-
nostically useful information. At the end of the interview, the 
clinical psychologist had to judge whether the subject showed 
no anxiety/depression or one or both of these characteristics. 
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If this was the case, the subject was invited to attend further 
sessions for clinical psychological support.
statistical analysis
R software 3.3.0 (R Foundation for Statistical Computing, 
Vienna, Austria. URL https://www.R-project.org/.; language 
and environment for statistical computing and graphics)26 was 
used to analyze the data sample and analysis of variance to 
verify the significance of the differences in mean QD-R and 
STAI-X3 scores between males and females and between the 
disease groups. The construct validity of the AD-R schedule 
as a measure of depression and anxiety was assessed by 
examining the differences in mean value between the clini-
cal groups as classified by the psychologist. Bonferroni’s 
correction was applied for the type I error inflation due to 
multiple comparisons.
ROC curves were used to identify the AD-R cutoff points. 
ROC analysis quantifies the accuracy of diagnostic tests 
(or further appraisal types) used to discriminate between 
two states or conditions. The discriminatory accuracy of a 
diagnostic test is quantified by its ability to suitably classify 
between subjects with and without disease.27 A ROC plot 
displays the performance of a dichotomous classification 
procedure with continuous or discrete ordinal outcome. In the 
ROC space, the area under the curve (AUC) measures the 
performance of a classifying variable and is frequently applied 
for method comparison. A higher AUC means a better clas-
sification.28 AUCs are computed with trapezoids.29 In our case, 
ROC curves were used to identify the AD-R cutoff points. 
This technique is commonly used in medical decision-making 
research in order to determine how well a potential classifier 
discriminates two classes.27–32 In the context of this study, the 
potential classifying variables were the total AD-R scores, and 
the two classes were the binary classification of the presence/
absence of the clinically relevant psychological variables 
(anxiety and depression).
The confidence intervals (CIs) were computed with boot-
strap for AUCs.33 The 95% CIs of the AD-R cutoff points 
and the sensitivity and specificity values were computed with 
bootstrap resampling (stratified manner), and the averaging 
methods described by Fawcett.32 In all bootstrap CIs, the 
subjects were resampled and the modified curve was built 
before the statistics of interest were computed.
Results
One hundred and seventy-seven subjects (101 males and 
76 females) completed the AD-R schedule and the interview 
with the psychologist at the beginning of their in-hospital reha-
bilitation period. Tables 1 and 2 show their characteristics. The 
main pulmonary diseases were asthma, COPD, and respiratory 
failure; the main cardiac diseases were coronary artery disease 
(myocardial infarction, angina pectoris), congestive heart 
failure, and valvular heart disease; and the main neurological 
or neuromuscular diseases were stroke and myopathy.
Comparing the three disease groups, no significant differ-
ences were found either for STAI-X3 scores (F
(2,174)
=0.252, 
P=0.778) or for QD-R scores (F
(2,174)
)=0.186, P=0.830).
Table 3 shows the distribution of the AD-R scores on 
the basis of the psychologist’s diagnosis of depression and 
anxiety. Based on the psychologist’s judgment, 53 subjects 
were “possible case for anxiety” (prevalence =29.9%) and 
42 were “possible case for depression” (prevalence =23.7%). 
There was a significant difference in mean STAI-X3 scores 
between the subjects with and without clinically relevant 
anxiety (t
(175)
=14.813, P,0.001), and in mean QD-R scores 
between the subjects with and without clinically relevant 
depression (t
(175)
=12.864, P,0.001).
cutoff scores
The best AUC for STAI-X3 was obtained with a cutoff 
point of 21.0 for males and 25.0 for females (Figure 1). CI 
of AUC for STAI-X3 sample of males (equal to 95.5%) was 
Table 1 characteristics of the diseases
Disease 
group
Disease Disease number 
of subjects
Disease group 
number of subjects
Disease group 
age (mean ± SD)
Total number 
of subjects
cardiac 
disease
ischemic heart disease 67 110 61.6±11.1 177 (101 males 
76 females)Valvular heart surgery 27
heart failure 9
Other cardiac disease 6
Pulmonary 
disease
asthma 7 47 61.43±13.9
chronic obstructive pulmonary disease 24
Obstructive sleep apnea syndrome 10
Other respiratory disease 6
Neuromotor 
disease
Parkinson 7 20 62.0±12.2
stroke 7
Osteoarthritis 6
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92.0%–99.0%, whereas CI of AUC for STAI-X3 sample of 
females (equal to 92.9%) was 86.5%–99.4%.
The best AUC for QD-R was obtained with a cutoff point 
of 6.0 for males and 8.0 for females (Figure 2). CI of AUC for 
QD-R sample of males (equal to 94.9%) was 90.4%–99.4%, 
whereas CI of AUC for QD-R sample of females (equal to 
96.7%) was 92.8%–100.0%.
Table 4 shows the CIs of cutoff points of STAI-X3 and 
QD-R in male and female samples. The table also shows the 
sensitivity, specificity, positive predictive value (what is the 
probability that the disease is present when the test is positive) 
and negative predictive value (what is the probability that the 
disease is not present when the test is negative), positive likeli-
hood ratio (what is the ratio between the probability of a positive 
test result given the presence of the disease and the probability 
of a positive test result given the absence of the disease) and 
negative likelihood ratio (what is the ratio between the prob-
ability of a negative test result given the presence of the disease 
and the probability of a negative test result given the absence of 
the disease); 95% CIs for each index are also reported.
The difference between sexes in STAI-X3 scores was not 
significant (t
(175)
=-0.952, P=0.342), whereas female showed 
higher (t
(175)
=-2.415, P=0.017) QD-R scores (5.51±3.4) than 
male (4.37±3.2). The bootstrap test for ROCs (2,000 resampling) 
indicates that the differences between curves for males and 
females were not significant both for STAI X-3 (D =0.679, 
P-value =0.497), and QD-R (D =0.356, P-value =0.721).
Discussion
Granted that assessing depression and anxiety in patients 
undergoing rehabilitation in a hospital is of major importance, 
it is necessary to devise an efficient way of completing such 
assessments.34–38 In this study, we searched the cutoff score 
of the STAI-X3 and QD-R not referring particularly to the 
specific disease (ie, CHD, COPD), but to the hospitalized 
condition in general, considering that DSM criteria suggest 
to pay attention to symptoms that are clearly due to a general 
medical condition, not to a specific medical condition.24 When 
identifying a cutoff score for a routine screening, we also 
found that the QD-R was sensible and specific for a clinically 
relevant state of depression worthy of a deeper psychological 
examination, not to identify a major depressive disorder to be 
treated with antidepressants. This avoids the risk suggested 
by some authors11 that antidepressant medications may be 
initiated merely based on a positive depression screen.
From a clinical perspective, our findings support the use 
of AD-R cutoff scores as a means of screening psychological 
status in rehabilitation and hospital settings. Additionally, 
there were no differences between the disease groups. This 
would allow the multidisciplinary team to devise therapeutic 
interventions designed to improve both physical and psycho-
logical symptoms across disease conditions, which may be 
the best method to optimize functioning.39–44
The AD-R schedule is clearly subdivided in a solid mea-
sure of anxiety and another of depression, with different scores 
and cutoff points. Some questionnaires measuring depression 
focus narrowly on anhedonia, defined as a reduced ability to 
experience pleasure; it is too much to expect that ill patients 
will discriminate the intended meaning from their experience 
of not wanting to engage in previously pleasurable activities 
because of pain, fatigue, and other physical impairment.45
The use of ROC curves provide information concerning 
AD-R cutoff values, which allow psychologists to optimize 
early clinical interventions during rehabilitation or in the 
provision of secondary prevention by identifying a clini-
cally relevant state of depression and/or anxiety worthy of 
a deeper examination. In our sample, we found a STAI-X3 
cutoff point of 21 for males and 25 for females. This means 
that a score $21 for males and $25 for females is indica-
tive of a clinical level of anxiety that needs to be evaluated 
further by a psychologist. For QD-R, we found a cutoff point 
of 6 for males and 8 for females. This means that a score $6 
for males and $8 for females is indicative of a critical mood 
Table 2 characteristics of the sample
Cardiac
disease
Pulmonary  
disease
Neuromotor 
disease
employment status
employed 26 14 10
retired/housewife 78 30 10
Unemployed 2 0 0
Others 4 3 0
civil status
Married 79 30 5
Widower 17 9 0
Divorced/single 3 6 5
Others 11 2 10
Questionnaires
Mean score ± sD
sTai-X3 20.33±5.79 21.11±7.53 20.80±7.69
QD-r 4.84±2.92 4.66±3.91 5.20±3.89
Abbreviations: QD-r, questionnaire depression-reduced; sTai-X3, state anxiety 
inventory; sD, standard deviation.
Table 3 construct validity of the aD-r schedule
Clinical 
judgment
Depression Anxiety
Number 
of subjects
QD-R score
(mean ± SD)
Number 
of subjects
STAI-X3 score
(mean ± SD)
No 135 3.5±2.4 124 17.46±3.8
Yes 42 8.9±2.4 53 27.9±5.3
Abbreviations: aD-r, sTai-X3 and Depression Questionnaire-reduced Form; 
QD-r, questionnaire depression-reduced; sTai-X3, state anxiety inventory.
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Figure 1 rOc curves and cut-off scores for sTai-X3.
Notes: (A) rOc curve for sTai-X3, sample of males. (B) ROC curve for STAI-X3, sample of females. Both figures show the value of cutoff point (with the percentages of 
specificity and sensitivity) and the AUC (with 95% confidence interval).
Abbreviations: aUc, area under the curve; rOc, receiver operating characteristic; sTai-X3, state anxiety inventory.
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Figure 2 rOc curves and cut-off scores for QD-r.
Notes: (A) rOc curve for QD-r, sample of males. (B) ROC curve for QD-R, sample of females. Both figures show the value of cutoff point (with the percentages of 
specificity and sensitivity) and the area under the curve (AUC, with 95% confidence interval).
Abbreviations: aUc, area under the curve; QD-r, questionnaire depression-reduced; rOc, receiver operating characteristic.
Table 4 The ci of cutoff points of sTai-X3 and QD-r on the basis of the rOc method in relation to the clinical judgment expressed 
by the psychologist after the semistructured interview
Questionnaires 
(x sexes)
Cutoff 
point
Sensitivity 
(95% CI)
Specificity 
(95% CI)
PPV  
(95% CI)
NPV  
(95% CI)
PLR  
(95% CI)
NLR  
(95% CI)
sTai-X3 males 21.0 92.90%
(82.1%–100%)
86.30%
(78.1%–86.3%)
72.2%
(54.5%–86%)
96.9%
(89.3%–99.6%)
6.78%
(3.8%–12.2%)
0.08%
(0.02%–0.3%)
sTai-X3 females 25.0 88.0%
(76%–100%)
82.4%
(70.6%–92.2%)
70.9%
(51.5%–85.9%)
93.4%
(81.8%–98.8%)
4.99%
(2.7%–9.2%)
0.15%
(0.05%–0.4%)
QD-r males 6.0 86.7%
(66.7%–100%)
93.0%
(87.2%–97.7%)
68.3%
(42.6%–87.8%)
97.6%
(91.5%–99.7%)
12.42%
(5.6%–27.6%)
0.14%
(0.04%–0.5%)
QD-r females 8.0 88.9%
(70.9%–97.6%)
95.92%
(86.0%–99.5%)
92.3%
(74.9%–99.1%)
94.0%
(83.3%–98.8%)
21.78%
(18.8%–25.2%)
0.12%
(0.02%–0.7%)
Abbreviations: CI, confidence interval; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; QD-R, 
questionnaire depression-reduced; rOc, receiver operating characteristic; sTai-X3, state anxiety inventory.
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level suggestive of a level of depression that requires a more 
complete evaluation by a psychologist.
Regarding construct validity, we found higher cutoff 
scores in females compared to males, as has been report-
ed.23 These results may be due to sex differences in illness 
perception: females, compared to males, are more likely to 
attribute cardiovascular disease (CVD) to causes beyond 
their control and perceive CVD as a chronic, untreatable 
condition.46 Screening, especially for depression, is strongly 
recommended even in primary care.47 Furthermore, in our 
previous paper, QD-R scores significantly correlated with 
meters walked in the 6-m walking test by 252 patients during 
cardiovascular rehabilitation, and patients with QD-R scores 
ranging from 0 to 5 showed a progressive reduction in the 
total distance walked during the test. In that study, a fall in 
walking distance corresponded to a value of 6 in the depres-
sion score as measured by QD-R.14 Further research could 
be performed to observe the trend of functional performance 
along clinical cutoff points and to evaluate the effectiveness 
of integrated and multidisciplinary stepped care,48,49 and 
studies with hospitalized subjects.50–53
Limitations
We collected a sample from a single hospital; our results essen-
tially describe what was found in the sample, but the extent to 
which those results might generalize beyond the center where 
the study was conducted is unknown. We also studied patients 
with pulmonary, cardiac, or neurological and neuromuscular 
diseases with very heterogeneous characteristics. However, 
this situation reproduces the proportion of patients usually 
followed by a psychologist during the rehabilitation phase 
in our institute. Further study with a larger sample and with 
different diseases would be required to test the validity of the 
AD-R cutoff scores for the screening of hospitalized patients 
that need a specific psychological support.
Conclusion
Using these cutoff values, the STAI-X3 and QD-R allow psy-
chologists to optimize early clinical intervention strategies.
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